Scientific Reports - <ArticleTitle Language="En" xml:lang="en">Long term outcomes in survivors of epidemic Influenza A (H7N9) virus...
No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups Infected with SARS-CoV-2 Delta Variant
We found no significant difference in cycle threshold values between vaccinated and unvaccinated, asymptomatic and symptomatic groups infected with SARS-CoV-2 Delta. Given the substantial proportion of asymptomatic vaccine breakthrough cases with high viral levels, interventions, including masking and testing, should be considered for all in settings with elevated COVID-19 transmission.
### Competing Interest Statement
Dr. DeRisi reports being a scientific advisor to the Public Health Co. and a scientific advisor to Allen & Co. Dr. Havlir reports non-financial support from Abbott outside of the submitted work. The other authors declare no competing interests.
### Funding Statement
This work was supported by the Chan Zuckerberg Biohub, Healthy Yolo Together, the University of California, San Francisco, the Chan Zuckerberg Initiative, and The University of California, Davis.
### Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
HYT: The Genome Center laboratory that conducted COVID-19 testing was CLIA approved as an extension to the Student Health Center laboratory. The UC Davis IRB Administration determined that the study met criteria for public health reporting and was exempt from IRB review and approval. UeS: The UC San Francisco Committee on Human Research determined the study met criteria for public health surveillance. All participants provided informed consent for testing.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data are available in the Supplementary Materials.
Wir fördern Wissenschaft. Über die Klinikgrenze hinaus. Und wir kümmern uns. Mit vernetzter Forschung um das Wohl unserer Patienten. Denn bei uns steht stets der Mensch im Fokus.
Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants
Emerging and future SARS-CoV-2 variants may jeopardize the effectiveness of vaccination campaigns. We performed a head-to-head comparison of the ability of sera from individuals vaccinated with either one of four vaccines (BNT162b2, mRNA-1273, AZD1222 or Ad26.COV2.S) to recognize and neutralize the four SARS-CoV-2 variants of concern (VOCs; Alpha, Beta, Gamma and Delta). Four weeks after completing the vaccination series, SARS-CoV-2 wild-type neutralizing antibody titers were highest in recipients of BNT162b2 and mRNA-1273 (median titers of 1891 and 3061, respectively), and substantially lower in those vaccinated with the adenovirus vector-based vaccines AZD1222 and Ad26.COV2.S (median titers of 241 and 119, respectively). VOCs neutralization was reduced in all vaccine groups, with the largest (5.8-fold) reduction in neutralization being observed against the Beta variant. Overall, the mRNA vaccines appear superior to adenovirus vector-based vaccines in inducing neutralizing antibodies against VOCs four weeks after the final vaccination.
### Competing Interest Statement
The authors have declared no competing interest.
### Funding Statement
the Netherlands Organization for Scientific Research (NWO) ZonMw (no. 10430022010023 no. 10150062010002 no. 91818627) the Bill & Melinda Gates Foundation (no. INV-002022 no. INV008818 no. INV-024617) the Amsterdam UMC through the AMC Fellowship and the Corona Research Fund the European Unions Horizon 2020 program (no. 101003589).
### Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The S3 study, the COSCA study and the RECoVERED study were approved by the medical ethical review board of the Amsterdam University Medical Centers (NL73478.029.20, NL73281.018.20 and NL73759.018.20, respectively). All participants provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
All data are available in the main text or supplementary materials. Reagents used in this study are available upon reasonable request under an MTA with Amsterdam UMC.
Divergence of delta and beta variants and SARS-CoV-2 evolved in prolonged infection into distinct serological phenotypes
SARS-CoV-2 continues to evolve variants of concern (VOC) which escape antibody neutralization and have enhanced transmission. One variant may escape immunity elicited by another, and the delta VOC has been reported to escape beta elicited immunity. Systematic mapping of the serological distance of current and emerging variants will likely guide the design of vaccines which can target all variants. Here we isolated and serologically characterized SARS-CoV-2 which evolved from an ancestral strain in a person with advanced HIV disease and delayed SARS-CoV-2 clearance. This virus showed evolving escape from self antibody neutralization immunity and decreased Pfizer BNT162b2 vaccine neutralization sensitivity. We mapped neutralization of evolved virus and ancestral, beta and delta variant viruses by antibodies elicited by each VOC in SARS-CoV-2 convalescent individuals. Beta virus showed moderate (7-fold) and delta slight escape from neutralizing immunity elicited by ancestral virus infection. In contrast, delta virus had stronger escape from beta elicited immunity (12-fold), and beta virus even stronger escape from delta immunity (34-fold). Evolved virus had 9-fold escape from ancestral immunity, 27-fold escape from delta immunity, but was effectively neutralized by beta immunity. We conclude that beta and delta are serologically distant, further than each is from ancestral, and that virus evolved in prolonged infection during advanced HIV disease is serologically close to beta and far from delta. These results suggest that SARS-CoV-2 is diverging into distinct serological phenotypes and that vaccines tailored to one variant may become vulnerable to infections with another.
### Competing Interest Statement
The authors have declared no competing interest.
### Funding Statement
This study was supported by the Bill and Melinda Gates award INV-018944 (AS), National Institutes of Health award R01 AI138546 (AS), South African Medical Research Council awards (AS, TdO, PLM) and National Institutes of Health U01 AI151698 (WVV). PLM is supported by the South African Research Chairs Initiative of the Department of Science and Innovation and the NRF (Grant No 9834). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
### Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Nasopharyngeal and oropharyngeal swab samples and plasma samples were obtained from hospitalized adults with PCR confirmed SARS-CoV-2 infection who were enrolled in a prospective cohort study approved by the Biomedical Research Ethics Committee at the University of KwaZulu Natal (reference BREC/00001275/2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
All data available in the manuscript, GISAID SARS-CoV-2 sequence repository, or upon reasonable request from the authors.
Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel
Background Starting December 2020, Israel began a mass vaccination campaign against coronavirus administering the Pfizer BNT162b2 vaccine, which led to a sharp curtailing of the outbreak. After a period with almost no SARS-CoV-2 infections, a resurgent COVID-19 outbreak initiated mid June 2021. Possible reasons for the breakthrough were reduced vaccine effectiveness against the Delta variant, and waning immunity. The aim of this study was to quantify the extent of waning immunity using Israel’s national-database.
Methods Data on all PCR positive test results between July 11-31, 2021 of Israeli residents who became fully vaccinated before June 2021 were used in this analysis. Infection rates and severe COVID-19 outcomes were compared between individuals who were vaccinated in different time periods using a Poisson regression, stratifying by age group and adjusting for possible confounding factors.
Results The rates of both documented SARS-CoV-2 infections and severe COVID-19 exhibit a statistically significant increase as time from second vaccine dose elapsed. Elderly individuals (60+) who received their second dose in March 2021 were 1.6 (CI: [1.3, 2]) times more protected against infection and 1.7 (CI: [1.0, 2.7]) times more protected against severe COVID-19 compared to those who received their second dose in January 2021. Similar results were found for different age groups.
Conclusions These results indicate a strong effect of waning immunity in all age groups after six months. Quantifying the effect of waning immunity on vaccine effectiveness is critical for policy makers worldwide facing the dilemma of administering booster vaccinations.
### Competing Interest Statement
The authors have declared no competing interest.
### Funding Statement
No funding.
### Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board of the Sheba Medical Center. Helsinki approval number: SMC-8228-21.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Aggregated data are given in the supplementary information. Personal data cannot be shared due to privacy.
(5) Ofra Amir auf Twitter: "A new pre-print of a study showing a detailed analysis of waning immunity in Israel: https://t.co/3OwrnDTpV6 TL/DR: infection rate and severe disease rates both significantly increase with vaccine age (thread)" / Twitter
A new pre-print of a study showing a detailed analysis of waning immunity in Israel: https://t.co/3OwrnDTpV6
TL/DR: infection rate and severe disease rates both significantly increase with vaccine age (thread)
(5) מואיז הקטן ® auf Twitter: "---Severe COVID-19 patients, ages 12-60 in ISRAEL--- . Only 19% of the population are unvaccinated and are responsible for 78% of the severely hospitalized. . Only 2 patients under the age of 20 so without them it is only 15% who are not vaccinated. https://t.co/NX4EQ2uIjg" / Twitter
---Severe COVID-19 patients, ages 12-60 in ISRAEL---
.
Only 19% of the population are unvaccinated and are responsible for 78% of the severely hospitalized.
.
Only 2 patients under the age of 20 so without them it is only 15% who are not vaccinated. https://t.co/NX4EQ2uIjg
(4) Yair Lewis auf Twitter: "@EricTopol @CellCellPress Adding some context from Israel: 1. The analysis by Israel MoH specifically stated that symptomatic infections weren’t analysed d/t data issues 2. VE for severe disease is 94% after 6m+ in 40-59yo, accdn’g to Israel MoH analysis https://t.co/Tga9vb6Flv" / Twitter
@EricTopol @CellCellPress Adding some context from Israel:
1. The analysis by Israel MoH specifically stated that symptomatic infections weren’t analysed d/t data issues
2. VE for severe disease is 94% after 6m+ in 40-59yo, accdn’g to Israel MoH analysis https://t.co/Tga9vb6Flv
Bilanz des PEI: Deutlich mehr Kinder mit Impfreaktion als mit COVID-19-Diagnose im Krankenhaus
Herzentzündungen, Embolien und die ersten Toten: Nach Beginn der Impfkampagne für Kinder und Jugendliche ab zwölf Jahren häufen sich die Verdachtsmeldungen möglicher Impfschäden auch in dieser Altersgruppe. Das geht aus dem neuen Bericht des Paul-Ehrlich-Instituts bis Ende August hervor. Und wahrscheinlich ist das nur die Spitze des Eisbergs.
Johann Holzmann auf Twitter: "Schauen wir nach Deutschland Im Prinzip das Gleiche in blau. Das Verhältnis der tgl. bis zu 30.000 COVID19 Fälle in KW50/51 zu den bis zu 1.5 Millionen geimpften Menschen pro Tag ist gut erkennbar. Die 30.000 COVID19 Fälle Ende 2020 führten zu einer deutlichen 10/n https://t.co/U5MoqwhJZV" / Twitter
Schauen wir nach Deutschland
Im Prinzip das Gleiche in blau. Das Verhältnis der tgl. bis zu 30.000 COVID19 Fälle in KW50/51 zu den bis zu 1.5 Millionen geimpften Menschen pro Tag ist gut erkennbar.
Die 30.000 COVID19 Fälle Ende 2020 führten zu einer deutlichen
10/n https://t.co/U5MoqwhJZV
COVID-19 vaccine effectiveness against hospitalizations and ICU admissions in the Netherlands, April- August 2021
The objective of this study was to estimate vaccine effectiveness (VE) against COVID-19 hospitalization and ICU admission, per period according to dominating SARS-CoV-2 variant (Alpha and Delta), per vaccine and per time since vaccination. To this end, data from the national COVID-19 vaccination register was added to the national register of COVID-19 hospitalizations. For the study period 4 April – 29 August 2021, 15,571 hospitalized people with COVID-19 were included in the analysis, of whom 887 (5.7%) were fully vaccinated. Incidence rates of hospitalizations and ICU admissions per age group and vaccination status were calculated, and VE was estimated as 1-incidence rate ratio, adjusted for calendar date and age group in a negative binomial regression model. VE against hospitalization for full vaccination was 94% (95%CI 93-95%) in the Alpha period and 95% (95%CI 94-95%) in the Delta period. The VE for full vaccination against ICU admission was 93% (95%CI 87-96%) in the Alpha period and 97% (95%CI 97-98%) in the Delta period. VE was high in all age groups and did not show waning with time since vaccination up to 20 weeks after full vaccination.
### Competing Interest Statement
The authors have declared no competing interest.
### Funding Statement
This work was funded by the Dutch Ministry of Health, Welfare and Sports.
### Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Centre for Clinical Expertise at the RIVM assessed the research proposal. They verified whether the work complies with the specific conditions as stated in the law for medical research involving human subjects (WMO), and were of the opinion that the research does not fulfill one or both of these conditions and therefore conclude it is exempted for further approval by the ethical research committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The primary data is not publicly available. Aggregated tables of these data are made available weekly at the website of the RIVM.
Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients over six months
Background and Objectives While most maintenance dialysis patients exhibit initial seroresponse to vaccination, concerns remain regarding the durability of this antibody response. This study evaluated immunity over time.
Design, setting, participants, and measurements This retrospective cohort study included maintenance dialysis patients from a midsize national dialysis provider who received a complete SARS-CoV-2 vaccine series and had at least one antibody titer checked after full vaccination. Immunoglobulin G spike antibodies (SAb-IgG) titers were assessed monthly with routine labs beginning after full vaccination and followed over time; the semiquantitative SAb-IgG titer reported a range between 0 and ≥ 20 U/L. Descriptive analyses compared trends over time by prior history of COVID-19 and type of vaccine received. Time-to-event analyses were conducted for the outcome of loss of seroresponse (SAb-IgG < 1 U/L or development of COVID-19). Cox proportional hazards regression was used to adjust for additional clinical characteristics of interest.
Results Among 1898 maintenance dialysis patients, 1567 (84%) had no prior history of COVID-19. Patients without a history of COVID-19 had declining titers over time. Among 441 BNT162b2/Pfizer recipients, median [IQR] SAb-IgG titer declined from 20 [5.99-20] U/L in month 1 to 1.30 [0.15-3.59] U/L by month 6. Among 779 mRNA-1273/Moderna recipients, median [IQR] SAb-IgG titer declined from 20 [20-20] in month 1 to 6.20 [1.74-20] by month 6. The 347 Ad26.COV2.S/Janssen recipients had a lower titer response than mRNA vaccine recipients over all time periods. In time-to-event analyses, Ad26.COV2.S/Janssen and mRNA-1273/Moderna recipients had the shortest and longest time to loss of seroresponse, respectively. The maximum titer reached in the first two months after full vaccination was predictive of the durability of the SAb-IgG seroresponse; patients with SAb-IgG titer 1-19.99 U/L were more likely to have loss of seroresponse compared to patients with SAb-IgG titer ≥ 20 U/L (HR 23.9 [95% CI: 16.1-35.5]).
Conclusions Vaccine-induced seroresponse wanes over time among maintenance dialysis patients across vaccine types. Early titers after full vaccination predict the durability of seroresponse.
### Competing Interest Statement
The authors have declared no competing interest.
### Funding Statement
CMH receives support from ASN KidneyCure's Ben J. Lipps Research fellowship. CMH's funder had no role in study design, data collection, reporting, or the decision to submit. Mr. Aweh, Dr. Manley, Mr. Ladik, Ms. Frament, Dr. Johnson and Dr. Lacson Jr are all employees of DCI, where Dr. Johnson is Vice Chair of the Board. Dr. Weiner, Dr. Miskulin, Dr. Agyropoulos, Dr. Abreo, Dr. Chin, Dr. Gladish, and Dr. Salman receive salary support to their institution from DCI.
### Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the WCG IRB Work Order 1-1456342-1.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data are available upon request.
COVID19 vaccine type and humoral immune response in patients receiving dialysis
Patients on dialysis vaccinated with the attenuated adenovirus SARS-CoV-2 vaccine might mount an impaired response to vaccination.We evaluated the humoral vaccination response among 2,099 fully vaccinated patients receiving dialysis. We used commercially ...
Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera
Abstract
19 On August 30, 2021, the WHO classified the SARS-CoV-2 Mu variant (B.1.621
20 lineage) as a new variant of interest. The WHO defines “comparative assessment of
21 virus characteristics and public health risks” as primary action in response to the
22 emergence of new SARS-CoV-2 variants. Here, we demonstrate that the Mu variant
23 is highly resistant to sera from COVID-19 convalescents and BNT162b2-vaccinated
24 individuals. Direct comparison of different SARS-CoV-2 spike proteins revealed that
25 Mu spike is more resistant to serum-mediated neutralization than all other currently
26 recognized variants of interest (VOI) and concern (VOC). This includes the Beta
27 variant (B.1.351) that has been suggested to represent the most resistant variant to
28 convalescent and vaccinated sera to date (e.g., Collier et al, Nature, 2021; Wang et
29 al, Nature, 2021). Since breakthrough infection by newly emerging variants is a
30 major concern during the current COVID-19 pandemic (Bergwerk et al., NEJM,
31 2021), we believe that our findings are of significant public health interest. Our results
32 will help to better assess the risk posed by the Mu variant for vaccinated, previously
33 infected and naïve populations.
Das DocMedicus Gesundheitslexikon informiert Sie über individuelle Vorsorgemaßnahmen (Prävention) inklusive Impfungen, Diagnostik und Therapie von Erkrankungen, Labormedizin, Medizingerätediagnostik etc.
Infection fatality rate of COVID-19 in community-dwelling populations with emphasis on the elderly: An overview
Background: The infection fatality rate (IFR) of Coronavirus Disease 2019 (COVID-19) varies
widely according to age and residence status.
Purpose: Estimate the IFR of COVID-19 in community-dwelling elderly populations and other age
groups from seroprevalence studies. Study protocol: https://osf.io/47cgb.
Data Sources: Seroprevalence studies done in 2020 and identified by any of four existing systematic
reviews.
Study Selection: SARS-CoV-2 seroprevalence studies with ≥1000 participants aged ≥70 years that
presented seroprevalence in elderly people; aimed to generate samples reflecting the general
population; and whose location had available data on cumulative COVID-19 deaths in elderly
(primary cutoff ≥70 years; ≥65 or ≥60 also eligible).
Data Extraction: We extracted the most fully adjusted (if unavailable, unadjusted) seroprevalence
estimates and sampling procedure details. We also extracted age- and residence-stratified cumulative
COVID-19 deaths (until 1 week after the seroprevalence sampling midpoint) from official reports,
and population statistics, to calculate IFRs corrected for unmeasured antibody types. Sample size-
weighted IFRs were estimated for countries with multiple estimates. Secondary analyses examined
data on younger age strata from the same studies.
Data Synthesis: Twenty-three seroprevalence surveys representing 14 countries were included.
Across all countries, the median IFR in community-dwelling elderly and elderly overall was 2.4%
(range 0.3%-7.2%) and 5.5% (range 0.3%-12.1%). IFR was higher with larger proportions of people
>85 years. Younger age strata had low IFR values (median 0.0027%, 0.014%, 0.031%, 0.082%,
0.27%, and 0.59%, at 0-19, 20-29, 30-39, 40-49, 50-59, and 60-69 years).
Limitations: Biases in seroprevalence and mortality data.
Conclusions: The IFR of COVID-19 in community-dwelling elderly people is lower than previously
reported. Very low IFRs were confirmed in the youngest populations.
SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration
The post-infection of COVID-19 includes a myriad of neurologic symptoms including neurodegeneration. Protein aggregation in brain can be considered as one of the important reasons behind the neurodegeneration. SARS-CoV-2 Spike S1 protein receptor binding ...
Public acceptance of COVID-19 vaccines: cross-national evidence on levels and individual-level predictors using observational data
Objectives The management of the COVID-19 pandemic hinges on the approval of safe and effective vaccines but, equally importantly, on high vaccine acceptance among people. To facilitate vaccine acceptance via effective health communication, it is key to understand levels of vaccine scepticism and the demographic, psychological and political predictors. To this end, we examine the levels and predictors of acceptance of an approved COVID-19 vaccine.
Design, setting and participants We examine the levels and predictors of acceptance of an approved COVID-19 vaccine in large online surveys from eight Western democracies that differ in terms of the severity of the pandemic and their response: Denmark, France, Germany, Hungary, Sweden, Italy, UK and USA (total N=18 231). Survey respondents were quota sampled to match the population margins on age, gender and geographical location for each country. The study was conducted from September 2020 to February 2021, allowing us to assess changes in acceptance and predictors as COVID-19 vaccine programmes were rolled out.
Outcome measure The outcome of the study is self-reported acceptance of a COVID-19 vaccine approved and recommended by health authorities.
Results The data reveal large variations in vaccine acceptance that ranges from 83% in Denmark to 47% in France and Hungary. Lack of vaccine acceptance is associated with lack of trust in authorities and scientists, conspiratorial thinking and a lack of concern about COVID-19.
Conclusion Most national levels of vaccine acceptance fall below estimates of the required threshold for herd immunity. The results emphasise the long-term importance of building trust in preparations for health emergencies such as the current pandemic. For health communication, the results emphasise the importance of focusing on personal consequences of infections and debunking of myths to guide communication strategies.
Data are available in a public, open access repository at Open Science Framework: .
(PDF) Premature ovarian failure -A long COVID sequelae
PDF | Ever since its emergence since 2019, Coronavirus Disease 2019 (COVID-19) has brought the healthcare setup down with its burden of varied... | Find, read and cite all the research you need on ResearchGate
Risk factors for SARS-CoV-2 infection and hospitalisation in children and adolescents in Norway: A nationwide population-based study
Objective To determine risk factors for SARS-CoV-2 infection and hospitalisation among children and adolescents.
Design Nationwide, population-based cohort study. Setting: Norway from 1 March 2020 to 31 April 2021. Participants: All Norwegian residents
Child mortality in England during the COVID-19 pandemic
Objectives Using the National Child Mortality Database (NCMD), this work aims to investigate and quantify the characteristics of children dying of COVID-19, and to identify any changes in rate of childhood mortality during the pandemic.
Design We compared the characteristics of the children who died in 2020, split by SARS-CoV-2 status. A negative binomial regression model was used to compare mortality rates in lockdown (23 March–28 June), with those children who died in the preceding period (6 January–22 March), as well as a comparable period in 2019.
Setting England.
Participants Children (0–17 years).
Main outcome measures Characteristics and number of the children who died in 2020, split by SARS-CoV-2 status.
Results 1550 deaths of children between 6th of January and 28 June 2020 were notified to the NCMD; 437 of the deaths were linked to SARS-CoV-2 virology records, 25 (5.7%) had a positive PCR result. PCR-positive children were less likely to be white (37.5% vs 69.4%, p=0.003) and were older (12.2 vs 0.7 years, p